Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911676 · ClinicalTrials.gov registry record · Phase 2
Translational Neuroscience Optimization of GlyT1 Inhibitor
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT01911676 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 71 participants.
The verdict
NCT01911676, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this study is to test the efficacy of treatment with one of two does of a glycine transporter inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function. Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I) and placebo twice daily in addition to their antipsychotic medication for 2 treatment periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout period lasting approximately 3 weeks.
Interventions
- DRUG Placebo
- DRUG PF-03463275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911676
The ClinicalTrials.gov registry entry for NCT01911676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01911676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01911676 about?
NCT01911676 is a clinical study titled "Translational Neuroscience Optimization of GlyT1 Inhibitor". This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this study is to test the efficacy of treatment with one of two does of a glycine transporter inhibitor (GlyT1I) combined...
What is the current status of trial NCT01911676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2013-08. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01911676?
The interventions under investigation include: Placebo (DRUG), PF-03463275 (DRUG).
Who is sponsoring clinical trial NCT01911676?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.